Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
Sponsor: Avidity Biosciences, Inc.
Listed as NCT05747924, this PHASE1/PHASE2 trial focuses on Atrophies, Facioscapulohumeral and Atrophy, Facioscapulohumeral and remains ongoing. Sponsored by Avidity Biosciences, Inc., it has been updated 15 times since 2023, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
15 versions recorded-
May 2025 — Present [monthly]
Active Not Recruiting PHASE1/PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2024 — May 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 10 earlier versions
-
Jan 2024 — Mar 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2023 — Jun 2023 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2023 — Apr 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Avidity Biosciences, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .